Form 4: TENAX CEO Giordano Reports Stock & Option Holdings

TENAX THERAPEUTICS CEO Christopher Thomas Giordano filed a Form 4 detailing his beneficial ownership of common stock and various stock options.

Summary

• Christopher Thomas Giordano, CEO and Director of TENAX THERAPEUTICS, INC. (TENX), directly owns 2,605 shares of common stock.
• He holds 450,000 stock options with an exercise price of $13.3, granted on January 9, 2026, which will vest 25% on January 9, 2027, and then 1/36th monthly for 36 months, expiring January 9, 2036.
• He holds 157 stock options with an exercise price of $3,152, which vested 25% annually from July 6, 2022, to July 6, 2025, expiring July 6, 2031.
• He holds 125 stock options with an exercise price of $992, which will vest 25% annually from June 9, 2023, to June 9, 2026, expiring June 9, 2032.
• He holds 437 stock options with an exercise price of $3.549, which will vest 25% annually from May 17, 2025, to May 17, 2028, expiring May 17, 2034.
• He holds 1,250,000 stock options with an exercise price of $5.94, exercisable as of December 10, 2025, expiring December 10, 2034.
• He holds 1,400,000 stock options with an exercise price of $5.89, which will vest 25% on May 16, 2026, and then 1/36th monthly for 36 months, expiring May 16, 2035.
• All option vesting is contingent upon Christopher Thomas Giordano's continued employment.

Sentiment

Score: 5

Explanation: The filing is a factual report of insider ownership and option grants, which is neutral in sentiment. It does not contain information that would inherently be positive or negative for the company's operational performance or financial health.

Positives

• The CEO's significant stock option holdings align his long-term financial interests with those of shareholders, incentivizing value creation.
• The structured vesting schedules demonstrate a commitment to retaining key management over several years.

Negatives

• Some reported option exercise prices ($3,152 and $992) appear unusually high, which could indicate past stock splits or reverse splits that might make these options significantly out-of-the-money if not adjusted for current stock price context.

Risks

• Vesting of all stock options is subject to the CEO's continued employment, meaning unvested options would be forfeited upon departure.
• The ultimate value of the stock options is directly dependent on the future performance and market price of TENAX THERAPEUTICS, INC.'s common stock.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider beneficial ownership and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The grants of stock options to Christopher Thomas Giordano, the CEO and Director, represent compensation arrangements between the company and a related party.

Stakeholder Impact

• Shareholders: The CEO's substantial equity and option holdings align his financial interests with those of shareholders, potentially incentivizing decisions that enhance long-term stock value.
• Employees: The structure of executive compensation, particularly the long-term vesting, can set a precedent for other employees' incentive plans and signal stability in leadership.

Next Steps

• Continued vesting of various stock options for Christopher Thomas Giordano on specified future dates, contingent on his continued employment.

Key Dates

Keywords

TENX, Form 4, Insider Ownership, Stock Options, CEO Compensation, Beneficial Ownership, Equity Incentives, Corporate Governance